Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Blood Rev. 2019 Jan;33:43-52. doi: 10.1016/j.blre.2018.07.001. Epub 2018 Jul 5.
Promising results from pre-clinical studies on the naturally-occurring polyphenol resveratrol have generated considerable interest and somewhat excessive expectations regarding the therapeutic potential of this compound for treating or preventing various diseases, including cardiovascular and neurodegenerative disorders and cancer. Resveratrol has potent inhibitory activity in vitro against various tumor types, including cell lines derived from virtually all blood malignancies. Pharmacological studies have shown that resveratrol is safe for humans but has poor bioavailability, due to its extensive hepatic metabolism. Curiously, a substantial proportion of the orally administered resveratrol can reach the bone marrow compartment. Notably, various pathways dysregulated in blood cancers are known to be molecular targets of resveratrol, thus substantiating the potential utility of this agent in blood malignancies. In this review, we primarily focus on the scientific evidence that supports the potential utility of resveratrol for the management of select hematological malignancies. In addition, potential clinical trials with resveratrol are suggested.
从天然多酚白藜芦醇的临床前研究中获得的有希望的结果，引发了人们对这种化合物在治疗或预防各种疾病（包括心血管和神经退行性疾病以及癌症）方面的治疗潜力的极大兴趣和一些过度的期望。白藜芦醇在体外对各种肿瘤类型具有强大的抑制活性，包括来自几乎所有血液恶性肿瘤的细胞系。药理研究表明，白藜芦醇对人类是安全的，但由于其广泛的肝脏代谢，生物利用度较差。奇怪的是，相当一部分口服给予的白藜芦醇可以到达骨髓腔。值得注意的是，血液癌中失调的各种途径是白藜芦醇的分子靶点，从而证实了该药物在血液恶性肿瘤中的潜在用途。在这篇综述中，我们主要关注支持白藜芦醇在管理某些血液恶性肿瘤方面的潜在用途的科学证据。此外，还提出了潜在的白藜芦醇临床试验。
